4D MOLECULAR THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
4D MOLECULAR THERAPEUTICS INC. - More news...
4D MOLECULAR THERAPEUTICS INC. - More news...
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Announces New Employment Inducement Grants
- 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
- 4DMT Announces New Employment Inducement Grants
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
- 4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
- 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
- 4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
- 4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
- 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
- 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
- 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
- 4DMT Announces Presentations at Upcoming Retina Conferences
- 4DMT to Participate in the 2024 Cantor Global Healthcare Conference
- 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
- 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
- 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
- 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
- 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
- 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
